Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904.
about
Lung cancer ablation: technologies and techniquesNovel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancerValidation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups.Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy.Outcomes of accelerated hypofractionated radiotherapy in stage i non-small-cell lung cancer.LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspectiveDisparities in treatment of patients with inoperable stage I non-small cell lung cancer: a population-based analysisRadiotherapy for a second primary lung cancer arising post-pneumonectomy: planning considerations and clinical outcomes.Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer.Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules.Hypofractionated 3D radiotherapy for inoperable T1-3 N0-1 non-small-cell lung cancer.New techniques for assessing response after hypofractionated radiotherapy for lung cancerStrategies of dose escalation in the treatment of locally advanced non-small cell lung cancer: image guidance and beyond.Triaging early-stage lung cancer patients into non-surgical pathways: who, when, and what?Accelerated hypofractionated radiation therapy (AHRT) for non-small-cell lung cancer: can we leave standard fractionation?DART-bid: dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily: high local control in early stage (I/II) non-small-cell lung cancer.
P2860
Q26827382-28DCC18A-2039-499F-9B65-309DCF5D8665Q26827571-7FA2A62D-4D5F-4CCB-89AA-C156AC7A7CCFQ30670518-0A110DD0-FEED-4118-B631-2DACD0414D7DQ30993385-D3DB3AF4-11A8-4D9E-832D-6280ECF80EAEQ34372246-672B8CD4-F163-4BA9-BE18-40CD5E8AE7D4Q36235727-8646041D-85BA-48A1-91E3-9F7571C2F9CCQ36729311-18180877-F6D7-4B13-8C58-2706F2DC3F42Q36753846-0378D6FB-D0B9-47C8-AE6E-9FB2FCFB3C91Q37333649-56BD8C45-8287-4F81-A9DD-F9A36940687AQ37367501-B8801B30-9CCF-480B-8EDE-A0C9B674F3EAQ37601085-A580AD0A-F497-489D-88BC-474B0BDF7A7BQ37670432-34402DB1-78DC-4343-A9CB-6A7F83758645Q38226816-5B278062-50ED-4F5E-91E1-31BECDC98590Q38962875-EA548DD7-DD36-4C7D-86A6-66097AF684ADQ40610439-638ED82F-0035-498D-BC53-6146FF50B21AQ53083823-AFDBAB41-D18F-472B-9185-89B3A8EA3FA6
P2860
Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase I study of accelerated c ...... nary dysfunction: CALGB 39904.
@ast
Phase I study of accelerated c ...... nary dysfunction: CALGB 39904.
@en
type
label
Phase I study of accelerated c ...... nary dysfunction: CALGB 39904.
@ast
Phase I study of accelerated c ...... nary dysfunction: CALGB 39904.
@en
prefLabel
Phase I study of accelerated c ...... nary dysfunction: CALGB 39904.
@ast
Phase I study of accelerated c ...... nary dysfunction: CALGB 39904.
@en
P2093
P2860
P356
P1476
Phase I study of accelerated c ...... nary dysfunction: CALGB 39904.
@en
P2093
A William Blackstock
Ajeet Gajra
Andrew T Turrisi
Jeffrey A Bogart
John Reilly
Lydia Hodgson
Mark R Green
Robert Lenox
Stephen L Seagren
Xiaofei Wang
P2860
P304
P356
10.1200/JCO.2009.25.0753
P407
P577
2009-11-23T00:00:00Z